Vor Biopharma Inc.

NasdaqGS:VOR Stock Report

Market Cap: US$1.3b

Vor Biopharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jean-Paul Kress

Chief executive officer

US$65.0m

Total compensation

CEO salary percentage0.53%
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenure1.1yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 18

Vor Biopharma: A Funded Replication Story With Franchise Potential

Summary Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust $514.5M liquidity position. VOR's global Phase 3 trials in myasthenia gravis and Sjögren’s are fully enrolled or underway, with topline MG data expected in H1 2027. Competitive pressures from argenx, Amgen, and Novartis require VOR to demonstrate differentiated efficacy, safety, and physician trust for commercial success. VOR remains a speculative clinical-value investment; disciplined capital allocation and successful global replication are critical to shifting from development to franchise. Read the full article on Seeking Alpha
Analysis Article • May 15

Companies Like Vor Biopharma (NASDAQ:VOR) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Vor Biopharma...
Analysis Article • Oct 11

Vor Biopharma Inc.'s (NASDAQ:VOR) Intrinsic Value Is Potentially 55% Above Its Share Price

Key Insights The projected fair value for Vor Biopharma is US$48.35 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • Sep 11

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jun 25

Calculating The Intrinsic Value Of Vor Biopharma Inc. (NASDAQ:VOR)

Key Insights Vor Biopharma's estimated fair value is US$0.31 based on 2 Stage Free Cash Flow to Equity Current share...
Analysis Article • Apr 08

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 24

Vor Biopharma: Short On Cash, Too Much Uncertainty For Now

Summary Vor Biopharma is developing novel cell therapies for AML, with trem-cel showing early promise in clinical trials but facing significant funding challenges. Trem-cel aims to enhance relapse-free survival in AML by targeting CD33 on cancer cells while minimizing bone marrow damage. Despite a recent private placement extending their runway, VOR's cash position remains precarious, posing a risk of dilution and market volatility. Given the early stage of their therapies and financial hurdles, I recommend holding off on investment until further developments in 2025. Read the full article on Seeking Alpha
Analysis Article • Dec 24

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Sep 10

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 24

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Dec 05

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Aug 18

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • May 05

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 13

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Key Insights Vor Biopharma's estimated fair value is US$9.25 based on 2 Stage Free Cash Flow to Equity Vor Biopharma's...
Analysis Article • Oct 19

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 12

Vor Bio appoints Eyal C. Attar as chief medical officer

Vor Bio (NASDAQ:VOR) appoints more than 20 years of demonstrated clinical experienced Eyal C. Attar as Chief Medical Officer.  Dr. Attar most recently served as senior vice president and CMO for Aprea Therapeutics.

CEO Compensation Analysis

How has Jean-Paul Kress's remuneration changed compared to Vor Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

US$628m

Mar 31 2026n/an/a

-US$883m

Dec 31 2025US$65mUS$345k

-US$696m

Compensation vs Market: Jean-Paul's total compensation ($USD65.03M) is above average for companies of similar size in the US market ($USD5.28M).

Compensation vs Earnings: Insufficient data to compare Jean-Paul's compensation with company performance.

CEO

Jean-Paul Kress (61 yo)

1.3yrs
Tenure
US$65,027,569
Compensation

Dr. Jean-Paul Kress, M.D., is Chairman, President & Chief Executive Officer of Vor Biopharma Inc. from June 25, 2025. Dr. Kress is Independent Director of Sanofi from January 1, 2025. Dr. Kress had been th...

Leadership Team

NamePositionTenureCompensationOwnership
Jean-Paul Kress
Chairman1.3yrsUS$65.03mno data
Sandesh Mahatme
Chief Business Officer & CFO1.2yrsUS$39.41mno data
Robert Ang
Strategic Advisor1.3yrsUS$3.36m0.011%
$ 136.9k
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
Adi Osovsky
General Counsel1yrno datano data
Carol Lincoln
Head of Human Resourcesno datano datano data
Dallan Murray
Chief Commercial Officer1.1yrsno datano data
Navid Khan
Chief Medical Affairs Officer1yrno datano data
Jeremy Sokolove
Chief Medical Officerless than a yearno datano data
1.1yrs
Average Tenure
55.5yo
Average Age

Experienced Management: VOR's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jean-Paul Kress
Chairman1.3yrsUS$65.03mno data
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
Malcolm Brenner
Scientific Advisor3.6yrsno datano data
Eric Sievers
Scientific & Clinical Advisorno datano datano data
Daniella Beckman
Lead Independent Director6.2yrsUS$64.20kno data
Olivier Danos
Scientific & Clinical Advisor4.9yrsno datano data
Steven Devine
Scientific & Clinical Advisorno datano datano data
Robert Soiffer
Scientific & Clinical Advisorno datano datano data
Alexander Cumbo
Independent Director1.2yrsUS$121.37k0%
$ 0
Hans-Peter Kiem
Scientific & Clinical Advisorno datano datano data
Fouad Namouni
Independent Director2.3yrsUS$51.09k0%
$ 0
Soheil Meshinchi
Scientific & Clinical Advisor5.7yrsno datano data
3.6yrs
Average Tenure
61yo
Average Age

Experienced Board: VOR's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/20 00:45
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vor Biopharma Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Carter GouldBarclays
Justin WalshB. Riley Securities, Inc.